Sarepta Therapeutics (SRPT) Net Equity Issued and Repurchased (2010 - 2020)
Sarepta Therapeutics (SRPT) posted quarterly Net Equity Issued and Repurchased of -$4.3 million for Q2 2020, down 4914.61% year-over-year from $89000.0 in Q3 2019, and down 101.35% quarter-over-quarter from $316.3 million in Q1 2020.
Sarepta Therapeutics (SRPT) Net Equity Issued and Repurchased (2010 - 2020) Analysis & Trends
Sarepta Therapeutics' Net Equity Issued and Repurchased history runs 11 years deep, the most recent figure standing at -$4.3 million for Q2 2020.
- In Q2 2020, Net Equity Issued and Repurchased fell 4914.61% year-over-year to -$4.3 million; the TTM figure through Dec 2024 stood at -$4.3 million (changed N/A YoY), while the FY2025 annual figure was $20.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q2 2020 stood at -$4.3 million, down from $316.3 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $470.4 million in Q4 2018, with the low at -$4.3 million in Q2 2020.
- The 5-year median for Net Equity Issued and Repurchased is $10.6 million (2018), against an average of $119.4 million.
- The sharpest annual moves came in 2016 and 2020: Net Equity Issued and Repurchased surged 7634.47% in 2016, then tumbled 4914.61% in 2020.
- Sarepta Therapeutics' Net Equity Issued and Repurchased stood at -$149000.0 in 2016, then soared by 234914.09% to $349.9 million in 2017, then jumped by 34.44% to $470.4 million in 2018, then plunged by 100.0% to $1000.0 in 2019, then slumped by 428600.0% to -$4.3 million in 2020.
- Business Quant data shows SRPT's Net Equity Issued and Repurchased at -$4.3 million in Q2 2020, $316.3 million in Q1 2020, and $1000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -4.29 Mn |
| Jun 30, 2020 | -4.29 Mn |
| Mar 31, 2020 | 316.34 Mn |
| Mar 31, 2020 | 316.34 Mn |
| Dec 31, 2019 | 1,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Jun 30, 2019 | 89,000.00 |
| Jun 30, 2019 | 89,000.00 |
| Mar 31, 2019 | 365.26 Mn |
| Mar 31, 2019 | 365.26 Mn |
| Dec 31, 2018 | 470.38 Mn |
| Dec 31, 2018 | 470.38 Mn |
| Sep 30, 2018 | 8.65 Mn |
| Sep 30, 2018 | 8.65 Mn |
| Jun 30, 2018 | 21.74 Mn |
| Jun 30, 2018 | 21.74 Mn |
| Mar 31, 2018 | 12.64 Mn |
| Mar 31, 2018 | 12.64 Mn |
| Sep 30, 2017 | 349.87 Mn |
| Sep 30, 2017 | 349.87 Mn |